Serina Therapeutics (NYSEAMERICAN:SER) Stock Price Down 1.8% – Here’s Why

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) was down 1.8% during trading on Friday . The stock traded as low as $2.64 and last traded at $2.80. Approximately 75,950 shares changed hands during mid-day trading, an increase of 69% from the average daily volume of 44,893 shares. The stock had previously closed at $2.85.

Wall Street Analysts Forecast Growth

Separately, BTIG Research started coverage on Serina Therapeutics in a report on Wednesday, July 1st. They set a “buy” rating and a $8.00 price target on the stock. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $8.00.

Serina Therapeutics Stock Down 1.8%

The company has a market cap of $42 million, a price-to-earnings ratio of -1.48 and a beta of 1.11. The stock has a 50-day simple moving average of $2.09 and a 200-day simple moving average of $2.02. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.24.

Serina Therapeutics (NYSEAMERICAN:SER) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.55) EPS for the quarter.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.